Merck & Co, Inc. has reported impressive financial results for the third quarter of 2025, surpassing market expectations and showcasing strong growth across its product lines. The company's performance was particularly driven by its oncology portfolio, with KEYTRUDA leading the charge, as enthusiastically stated in the publication.
Merck's Q3 2025 Sales Performance
In Q3 2025, Merck achieved total worldwide sales of $17.3 billion, reflecting a 4% increase compared to the same period in 2024. This growth was largely fueled by a 10% rise in KEYTRUDA sales, which reached $8.1 billion. The pharmaceutical segment's success was further supported by strong performances in
- oncology
- cardiovascular
- diabetes products
Standout Products and Earnings
A standout performer was WINREVAIR, which saw sales skyrocket by 141% to $360 million. Merck's GAAP earnings per share (EPS) stood at $2.32, while the non-GAAP EPS was reported at $2.58, both exceeding the expected EPS of $2.35. The company's net income surged by 83% to $5.8 billion, up from $3.2 billion in Q3 2024, driven by lower restructuring costs and a favorable product mix.
Strategic Approvals and Acquisitions
Merck's sales not only surpassed the anticipated revenue of $17.06 billion but also highlighted the impact of significant product approvals and strategic acquisitions. Notably, the FDA approved KEYTRUDA QLEX for subcutaneous use across all solid tumor indications, and the acquisition of Verona Pharma has bolstered Merck's pipeline in the cardiovascular and respiratory sectors.
The presale for Mutuum Finance has gained significant traction, entering its sixth phase with 80% of allocations already sold. This development contrasts with Merck's strong financial results, highlighting diverse market interests. For more details, see read more.
